doi: 10.1210/jc.2009-0212 26 SeneseRCioffiFde LangePGogliaFLanniA
Medicaid, the government program that covers 69 million Americans, covers GLP-1s for medically accepted conditions like diabetes, but only about a dozen state Medicaid programs cover GLP-1s for obesity treatment, according to KFF
Theoretical and Class-Level Risks These have not been confirmed in cagrilintide trials but are flagged because they appear in related amylin or GLP-1 class data: pancreatitis, gallbladder disease, severe hypoglycemia (mainly when combined with insulin or sulfonylureas), and acute kidney injury secondary to dehydration from severe nausea or vomiting
The compounded medication discussed here is not FDA-approved and is not intended to replace or substitute for FDA-approved GLP-1 therapies
Clinicians recommend not continuing GLP-1 medication while severe dehydration or other acute medical issues are being treated, and advise follow-up before restarting therapy
gingivalis , thereby reducing the overall oral microbial load and mitigating potential peripheral sources of inflammation